Medico Remedies Ltd. Share Price

Symbiotec Pharmalab

• Symbiotec Pharmalab is coming out with a 100% book building; initial public offering (IPO) of 1,87,34,736 shares of face value Rs 2 each in a price band Rs 938-988 per equity share. 
• Not more than 50% of the issue will be allocated to Qualified Institutional Buyers (QIBs), including 5% to the mutual funds. Further, not less than 15% of the issue will be available for the non-institutional bidders and the remaining 35% for the retail investors.
• The issue will open for subscription on August 24, 2026 and will close on August 27, 2026.
• The shares will be listed on BSE as well as NSE.
• The face value of the share is Rs 2 and is priced 469 times of its face value on the lower side and 494 times on the higher side.
• Book running lead managers to the issue are JM Financial, Avendus Capital, Motilal Oswal Investment Advisors and Nomura Financial Advisory and Securities (India).
• Compliance officer for the issue is Salil Jain. 

Profile of the company

The company is a research and development-driven, science-based pharmaceutical and biotechnology company with capabilities across three platforms- organic chemistry, biotechnology and complex injectables. It has a global leadership position in corticosteroid and steroidal-hormone active pharmaceutical ingredients (APIs). The company is the only Indian and global company to have a presence across the top 10 corticosteroid and steroidal-hormone APIs demonstrating the depth of its portfolio. It manufactures these products using fermentation and multi-step complex chemical reactions.

With over 30 years of industry experience, it has evolved from a labscale steroidal-hormone API manufacturer in 1995 into an industrial-scale, backward-integrated platform with approvals from the United States Food and Drug Administration (USFDA), European Union Good Manufacturing Practices (EU-GMP), Ministry of Food and Drug Safety, Korea and other global organisations. It has leveraged its deep capabilities across organic chemistry, biotechnology, and complex injectables to operate as a contract development and manufacturing organisation (CDMO) variably for specialty pharmaceutical and nutraceutical companies globally, offering products and services across the three platforms in which it also manufactures its own products.

The company has a robust product portfolio of over 60 corticosteroid and steroidal-hormone APIs that are supplied globally, including Hydrocortisones, Betamethasones, Methylprednisolones, Progesterones, Estrogens and Testosterones, which are used extensively in critical care setups, as well as across chronic therapeutic areas such as respiratory, dermatology, pain management, oncology and gynaecology. Its capabilities span three interlinked platforms: (i) organic chemistry, including flow chemistry, hydrogenation, and photochemistry; (ii) biotechnology, including biosynthesis and biotransformation, and recombinant biologics, including Glucagon-like Peptide-1 (GLP-1) and Insulins; and (iii) forward integration into complex injectables including double-chamber vials, double-chamber bags and double-chamber syringes, collectively enabling it to commercialise and scale hard-to-replicate products and services.

Proceed is being used for: 

• Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the company
• General corporate purposes

Industry overview

India has been aptly crowned the Pharmacy of the World, particularly for its manufacturing prowess and contributions to the global pharma sector. India is the largest provider of generic medicines worldwide, holding a 20% share in global supply by volume, encompassing a diverse range of 60,000 generic brands across 60 therapeutic categories. The industry's global reach is underscored by the fact that India exports pharmaceuticals to over 200 countries, supplying more than 50% of Africa's generic medicine needs, almost 40% of the generic demand in the US, and approximately 25% of all medicines in the UK.

India is among the largest global exporters of APIs, supported by efficient processes, regulatory expertise, scale, and cost advantages. API exports grew from $4.2 billion in 2020 to $4.9 billion in 2025, a CAGR of 3.1%, despite increased domestic consumption as local manufacturers supply more to Indian formulation companies. Exports are projected to reach $6.4 billion by 2030, reflecting a 5.5% CAGR from 2025 to 2030. Exports to regulated markets rose from $1.9 billion in 2020 to $2.3 billion in 2025 (3.9% CAGR) and are expected to reach $3.2 billion by 2030. Exports to emerging markets increased from $2.3 billion to $2.6 billion (2.5% CAGR) between 2020 and 2025 and are projected to reach $3.2 billion by 2030 (4.2% CAGR).

India’s deep-rooted credibility in highly regulated markets illuminates its end-to-end manufacturing competence. In Q1 2025, Indian companies accounted for 48% of all USDMF49 submissions. Additionally, in 2025, Indian companies operated more than 220 US FDA-approved API manufacturing facilities, significantly outpacing counterparts in the US and China. Additionally, India had 156 facilities approved for either formulations or formulations plus APIs, demonstrating its manufacturing capabilities50. This regulatory proficiency enables India to meet the global demand for APIs and FDFs seamlessly, offering a reliable, high-quality, and scalable supply base across various therapeutic categories.

Pros and strengths 

Long-standing relationships with domestic and global customer base: As of March 31, 2026, it served over 200 customers across more than 40 countries, supported by its strong focus on quality assurance, scale of operations and ability to ensure consistent supply of complex APIs. its customer portfolio comprises key generic and specialty pharmaceutical companies in global markets such as North America, Europe, and Asia, including several pharmaceutical majors and formulations companies. As of March 31, 2026, it had over 50 domestic customers and over 150 export customers. It has consistently added new customers over the last three Fiscals, contributing to continued expansion of its commercial footprint. In the Fiscals 2026, 2025 and 2024, it added 101, 96, and 89 new distinct customers.

Fully-invested, multi-scale, vertically integrated manufacturing platform with sustainable practices and clean regulatory track record: The company had two operational industrial-scale API manufacturing facilities and had commissioned two additional manufacturing facilities, leading to an aggregate maximum chemical synthesis capacity of 584.67 MT, fermentation capacity of 700 KL, and complex injectables capacity of 20 million vials. In addition, it is in the process of expanding its biologics capacity by adding a dedicated 14 KL (comprising two reactors of 7 KL each) fermentation capacity for biologics manufacturing at its proposed Biologics Facility in Ujjain, to cater to the increasing demand for GLP-1 and Insulin. As of March 31, 2026, it was among the few players in India to possess multi-scale fermenters, enabling it to produce both high-volume and low-volume fermentation-based products. This scale diversity also enables it to offer flexible CDMO services across various production volumes, including support for fermentation-based product development initiatives and complex injectables partners. The company has maintained a track record of regulatory adherence, having successfully completed 11 inspections from regulatory agencies and over 90 customers over the last three Fiscals, 2026. Notably, it has not received any critical observations from global regulators in course of their inspections during the last three Fiscals.

Continuous investment in R&D: Its innovation and an R&D-led development ethos have contributed to the growth of its operations and enabled it to build capabilities in industrial-scale steroidal and hormonal organic chemistry, as well as fermentation technologies across modalities ranging from bioconversion to biosynthesis and precision fermentation. Through continuous investment in R&D, it has evolved from a lab-scale manufacturer undertaking five to six step chemistry into an industrial-scale manufacturer with differentiated chemistry capabilities, enabling it to manufacture APIs and products collectively with up to 400 synthesis steps validated under cGMP efficiently. Its R&D capabilities support the development of complex, science and technology-based product offerings across APIs, fermentation-based products, complex injectables and drug–device combinations.

Robust financials with strong gross margins, high capital efficiency and cash conversion: The company has demonstrated a consistent track record of strong financial and operational performance. Its revenue from operations increased from Rs 7,162.47 million in Fiscal 2024 to Rs 7,515.54 million in Fiscal 2025 and further to Rs 8,691.49 million in Fiscal 2026, representing a CAGR of 10.16% between Fiscals 2024 and 2026, driven by robust global demand for its API products. Its high margin profile has been supported by a combination of improved product mix, increasing supplies to regulated markets, operational efficiencies, and controlled raw material prices. These factors have contributed to a significant improvement in its EBITDA margins, which increased from 24.48% in Fiscal 2024 to 27.26% in Fiscal 2025 and to 26.59% in Fiscal 2026, and it has already made investments into, and committed operational resources towards, its complex injectables and CDMO platform for future growth. Its financial performance and credit ratings reflect its disciplined financial management and prudent capital allocation practices.

Risks and concerns

High revenue concentration in API products: The company derives almost all of its revenue from the sale of APIs, which collectively constituted 96.07%, 99.10% and 100.00% of its revenue from operations in Fiscals 2026, 2025 and 2024, respectively. Further, its top five APIs constituted 62.27%, 63.16% and 60.37% of its revenue from operations in Fiscals 2026, 2025 and 2024, respectively. Any reduction in demand for APIs, and its top products in particular, or disruption in production, could have an adverse effect on its business, results of operations, financial condition and cash flows. Further, if its API production is interrupted due to equipment failure, supply chain disruptions, regulatory noncompliance, or other operational challenges, or if it fails to procure high-quality APIs in the quantities it requires on a cost-effective basis, the sales and distribution of its products could be delayed or interrupted.

Risks associated with export sales and overseas operations: The company exports its products to various countries, and its revenue from external customers outside India represented 67.04%, 55.19% and 59.97% of its revenue from operations in Fiscals 2026, 2025 and 2024, respectively. Its inability to manage the risks associated with its export sales could adversely affect its sales to customers in foreign countries, its results of operations, financial condition and cash flows. Further, as part of its overseas business operations, it may engage with government institutions and agencies in various jurisdictions. Such engagements expose it to risks including complex regulatory requirements, delays in decision-making, changes in government policies, and potential compliance challenges.

Dependence on top ten customers for revenue: The company derives a substantial portion of its revenue from certain key customers, including large pharmaceutical companies to whom it supplies products across multiple therapeutic categories. These customers rely on the company for consistent quality and timely delivery. Revenue generated from its top ten customers accounted for 57.59%, 55.90% and 61.65% of its revenue from sale of product in Fiscals 2026, 2025 and 2024, respectively. Loss of its relationship with any of these customers or delays or reductions in their orders could have an adverse effect on its business, results of operations, financial condition and cash flows. Further, since it does not maintain long-term contractual arrangements with its customers and rely on purchase orders, it is exposed to the risks of customer cancellations, delays, or order reductions, which could adversely affect its results of operations, financial condition and cash flows.

Supplier concentration and raw material supply chain risks: The company relies on securing timely supplies of raw materials for its manufacturing process. The company depends on certain suppliers for raw materials for its operations. Purchases from its top ten suppliers accounted for 25.50%, 18.41% and 50.33% of its total expenses in Fiscals 2026, 2025 and 2024, respectively. Any loss of such suppliers or non-performance of their obligations could adversely affect its business, results of operations, financial condition and cash flows. Its reliance on key suppliers presents several risks, including potential shortages of raw materials, increased costs, and reduced control over delivery schedules. Additionally, some suppliers may not have the capacity to handle sudden increases in orders for raw materials or may prioritise other customers over us. This uncertainty in its supply chain can result in increased costs as it may need to source materials at higher prices.

Outlook

Symbiotec Pharmalab is engaged in the business of manufacturing and selling of Active Pharmaceuticals Ingredientsvand Intermediates. It caters to both domestic and international markets. The company has a robust product portfolio of over 60 corticosteroid and steroidal-hormone APIs that are supplied globally, including Hydrocortisones, Betamethasones, Methylprednisolones, Progesterones, Estrogens and Testosterones, which are used extensively in critical care setups, as well as across chronic therapeutic areas such as respiratory, dermatology, pain management, oncology and gynaecology. On the concern side, the company procures a portion of its raw material requirements from different countries, including China and the United States. Any adverse developments in these countries, or the laws governing its imports from these countries, could disrupt its raw material supply and adversely affect its results of operations, financial condition and cash flows. further, it faces competition both within its API manufacturing business and in its role as a CDMO, which it has recently commenced. An inability to compete effectively may adversely affect its business, results of operations, financial condition and cash flows.

The issue has been offering 1,87,34,736 shares in a price band of Rs 938 -988 per equity share. The aggregate size of the offer is around Rs 1,757.32 crore to Rs 1,850.99 crore based on lower and upper price band respectively. Minimum application is to be made for 15 shares and in multiples thereon, thereafter. On performance front, its total income increased by 15.38% from Rs 7,559.79 million in Fiscal 2025 to Rs 8,722.58 million in Fiscal 2026. Its profit for the year was Rs 1,099.03 million in Fiscal 2026 compared to Rs 967.85 million in Fiscal 2025.

Meanwhile, in line with the R&D-focused ethos that has shaped its evolution, it intends to sustain and expand its innovation driven business model by consistently investing in technologies and strengthening its R&D infrastructure. For existing products, its focus will be on reducing manufacturing costs, and improving process efficiencies. Building on its track record of successfully developing complex molecules, such as conjugated estrogen products, it will continue to leverage its scientific expertise and integrated capabilities to address unmet global market opportunities. Its R&D ethos emphasises collaboration with global specialty pharmaceutical companies, academic institutions, and technology partners. It will also continue to invest in automation, digitalisation, and AI-driven process optimisation across its laboratories and manufacturing facilities to reinforce scalability, cost efficiency, and compliance with global regulatory standards, thereby accelerating its time to market.

Colinz Laboratories has informed that the 40thAGM of the Members of the Company is scheduled to be held on Tuesday the 22nd September, 2026, at 2.30 PM (IST) through Video Conferencing ('VC')/ Other Audio-Visual Means (‘OAVM’), as per the directive(s) of Ministry of Corporate Affairs and Securities and Exchange Board of India. As per section 108 of Companies Act,2013, read with Rule 20 of the Companies (Management and Administration) Rule, 2014 and all applicable provisions of the SEBI (LODR) Regulations, 2015, the Company is pleased to provide to its members the facility to cast their Vote(s) through remote e-voting starting from 19th September, 2026 (9.00 am) to 21st September, 2026 (5.00 pm), the cut-off date for remote e-voting is 15th September, 2026. E voting facility will also be available during AGM, to those members who did not exercise e voting during the above period. Pursuant to Regulation 42 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Section 91 of the Companies Act, 2013, the company has enclosed the details of Book Closure dates and calendar of events related to the 40th AGM of the Company.

The above information is a part of company’s filings submitted to BSE.  

Pursuant to Regulation 30 and other applicable provisions of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’), Sai Parenterals has informed that it enclosed copies of the Newspaper Advertisement published in PAS-1 by the Company with details regarding proposed change and variation in the objects of utilization of the Initial Public Offering (‘IPO’) proceeds, in compliance with requirement under the Companies Act, 2013. The advertisements were published today (ie. on 20th August, 2026) in the newspapers: Financial Express (English) and Mana Telangana (Telugu). The newspaper publications are also made available on its website at the following link https://www.saiparenterals.com/.

The above information is a part of company’s filings submitted to BSE.  

ABH Healthcare 

• ABH Healthcare is coming out with an initial public offering (IPO) of 34,29,600 shares in a price band of Rs 96 - 102 per equity share.
• The issue will open for subscription on August 24, 2026 and will close on August 27, 2026.
• The shares will be listed on SME Platform of NSE.
• The face value of the share is Rs 10 and is priced 9.60 times of its face value on the lower side and 10.20 times on the higher side.
• Book running lead manager to the issue is Fedex Securities.
• Compliance officer for the issue is Rahul Sharma.

Profile of the company

ABH Healthcare’s core focus is on providing specialised tertiary medical care in Tier 3 cities, within the state of Punjab while seeking to strike a balance between providing quality healthcare services and affordability. Located in Ferozepur, Punjab, its hospital has a capacity of 150 beds. Acquired by the company in 2022, the hospital was established in 1985 with 30 beds and is driven by a vision to provide affordable, accessible, and quality healthcare services, delivered with compassion. Since its acquisition, it has consistently invested in the hospital, expanding bed capacity, increasing its workforce, and introducing additional services and clinical specialties. It has 150 beds and offer 25 medical specialties in its hospital such as, cardiac sciences, neurology, minimally invasive spine and brain surgeries, gastroenterology, laparoscopic and bariatric surgery, urology, pulmonology, nephrology, ENT, maxillofacial surgeries, obstetrics and gynaecology, adult and neonatal critical care, orthopedics and joint replacement, neuro-psychiatry and drug de-addiction, general & laparoscopic surgery, dentistry, physiotherapy, dermatology and lab investigations and radiology. Its extensive 35+ years of experience in the healthcare industry in the region where it operates has helped it develop a strong understanding of the region’s market dynamics.

It has an extensive network of empanelment which includes, over 30 private and public health insurance companies and third-party administrators. In addition to private health insurance, it is also empaneled with all major government insurance schemes available in this region, including Ex-Servicemen Contributory Health Scheme (ECHS), Railways, Food Corporation of India (FCI), Bharat Sanchar Nigam (BSNL), and Ayushman Bharat - Sarbat Sehat Bima Yojana (AB SSBY). Its hospital has also received various accreditations including, the accreditations from the National Accreditation Board for Hospitals and Healthcare Providers (NABH) in 2021. Further, in the Fiscal 2025 it has also been accredited with NABH Digital Standards, highlighting its adoption of cutting-edge digital technologies in healthcare.

It has adopted comprehensive information technology ecosystem aimed at transforming both the patient and clinical experience, as well as boosting the business and operational efficiency. Central to its strategy is the adoption of cutting-edge technologies, including digitalizing its patient experience through its patient portal, website and widely-used messaging platforms. It has also implemented a state-of-the-art Computerized Physician Order Entry (CPOE) system and Electronic Health Record (EHR) platform, licensed from a third-party service provider. It has installed an inhouse Dell PowerEdge R660xs T40 Server for storage of data along with other data safety measures. Further, it has employed a professional to look after any kind of issues related to IT system.

Proceed is being used for:

• Repayment / prepayment, in part or full, of certain of its borrowings
• Funding its working capital requirements
• Funding inorganic growth through unidentified acquisitions and general corporate purposes

Industry overview

Healthcare has become one of India’s largest sectors, both in terms of revenue and employment. Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance and medical equipment. The Indian healthcare sector is growing at a brisk pace due to its strengthening coverage, services, and increasing expenditure by public as well as private players. India’s healthcare delivery system is categorised into two major components - public and private. The government, i.e., the public healthcare system, comprises limited secondary and tertiary care institutions in key cities and focuses on providing basic healthcare facilities in the form of Primary Healthcare Centers (PHCs) in rural areas. The private sector provides the majority of secondary, tertiary, and quaternary care institutions with a major concentration in metros, tier-I, and tier-II cities. 

The Indian healthcare sector was valued at Rs 9,42,590 crore ($110 billion) in 2016 and Rs 31,87,668 crore ($372 billion) in 2023. Healthcare spending accounted for 3.3% of India’s GDP in 2022 and is expected to rise to 5% by 2030, reflecting the sector’s increasing role in the economy. India continues to expand its healthcare infrastructure. As of February 2026, the country has 13,88,185 registered allopathic doctors and 7,51,768 AYUSH practitioners, supported by a growing workforce of 39.40 lakh nursing personnel. 

To strengthen capacity, there are 5,310 nursing institutions (including 806 government institutes) producing nearly 3.82 lakh nurses annually. Medical education capacity is also expanding, with 43 new medical colleges established in 2025-26, taking the total to around 818 medical colleges across India. The Government has also approved 11,682 MBBS seats and 8,967 postgraduate seats, with over 1,28,000 MBBS seats available annually, further strengthening the talent pipeline. Investment activity in the sector remains strong, with the hospital segment accounting for nearly 80% of the overall healthcare market, highlighting its important role in industry growth.

Pros and strengths

Delivering quality clinical care by attracting, retaining experienced and renowned clinicians: The cornerstone of delivering quality healthcare services lies in the quality of its clinicians and hence it has prioritized attracting and retaining renowned clinicians and other professionals who bring expertise and dedication to patient care. Not only its Promoter Directors namely, Dr. Saurabh Baghi and Dr. Vaishali Saini but, its team of key doctors have been experienced with institutes in India and overseas. Further, its senior doctors, such as Dr. Harsh Bholla (General Surgery) have been associated with it for over a decade while others like Dr. R.L. Taneja (General Surgery), Dr. Richa Arora (Obstetrics and Gynaecology) and Dr. Tajinder Bhalla (Orthopedics) have been associated with it for about 5 years. Most of its doctors are full-time consultants and are committed to its hospital for the long term. Further, it promotes its doctors by actively engaging in research and publishing several case reports in international journals. Its team of experienced clinicians and other professionals also enabled it to create and adhere to standardized clinical processes across its hospital. A large amount of autonomy is given to departmental head to drive their clinical practice providing greater flexibility in operations and freedom in decision making. These practices help it to retain well qualified doctors with its hospital and become a trusted name amongst its patient population.

Diversified operations across clinical specialties, payor mix and hospitals: It offers medical services across multiple specialties, covering a wide range of healthcare needs ensuring that it provides comprehensive, quality treatments across a wide spectrum of healthcare needs. Its facility serves as a one-stop solution, addressing both routine and complex medical conditions, and delivering personalized care that meets the unique needs of each patient. Whether it's preventive care, diagnostic services, or advanced treatments, it strives to be a trusted healthcare partner for all aspects of its patients' well-being. 

Comprehensive operating infrastructure including information technology and modern equipments: It has developed a comprehensive information technology infrastructure to support the delivery of its services to a broader population in need of healthcare. Combining advanced technology with an extensive service network has allowed it to address its patients' medical needs more effectively. Its technology initiatives are focused on improving patient experience, clinical workflows, and financial and operational efficiencies through process automation. It has established an information technology infrastructure to enhance the quality, affordability and accessibility of its services and reach more people in need of healthcare. The use of technology has enabled it to address the medical needs of its patients effectively. Its ongoing investment in new technologies, along with the upgrade and replacement of existing infrastructure, has led it to tailor its technology platforms to meet its specific requirements.

Risks and concerns

Revenue dependence on Punjab hospital:  It derives almost all of its revenue from operations from its only hospital in Ferozepur, Punjab. For instance, for the Fiscal 2026, and Fiscal 2025 and, its total revenue was Rs 5,104.37 lakh of which 100% and Rs 4,891.62 lakh of which 100% respectively were derived solely from the operations of its hospital in Ferozepur, Punjab. Any material impact on its revenues from its hospital in Ferozepur, Punjab, including by reason of a reduction in patient footfall, regulatory changes, reputational harm, liabilities on account of medical negligence, adverse publicity or natural calamities and increased competition, could have a material adverse effect on its business, financial condition and results of operations.

Hospital occupancy and capacity utilization risk: Its ability to sustain current levels of profitability and operating efficiencies depends on its ability to maintain and increase bed occupancy rates. It intends to focus on improving occupancy rates at its hospital. Improving occupancy rates at its hospital is highly dependent on factors such as brand recognition, wider acceptance in the communities in which it operates, its ability to attract and retain quality healthcare professionals, its ability to develop super-specialty practices and its ability to compete effectively with other hospitals and clinics. For instance, bed occupancy rate reduced from 70% in Fiscal 2022 to 65% in Fiscal 2023, while its total bed capacity increased from 75 beds to 85 beds during the corresponding period. Similarly, its bed occupancy rate reduced from 65% in Fiscal 2023 to 63% in Fiscal 2024, while its total bed capacity increased from 85 beds to 100 beds during the corresponding period. If it fails to improve its occupancy rates, but continue to incur significant expenditure in the future, this could materially adversely affect its operating efficiencies and its profitability.

Reliance on limited suppliers and subcontractors: It sources a majority of its medical supplies, drugs, pharmaceuticals and medical equipment for its operations from limited number of third-party suppliers. It also outsources various activities, such as cleaning and maintenance services, laboratory services, house-keeping and as well as security services, by entering into an arrangement/contract with original equipment manufacturers (OEM) and third-party suppliers. The use of third-party suppliers, OEMs and sub-contractors exposes it to supply chain bottlenecks, quality problems, reputational damage from their actions, and other potential liabilities or disruptions that may arise in cases where such third-party suppliers and sub-contractors fail to meet their commitments. It also relies on a limited number of equipment suppliers to carry out repairs and maintenance of its equipment. Any failure or negligence by such third parties in performing their obligations could adversely affect its business, financial condition, results of operations, reputation and brand. Further, any failure to procure equipment or supplies on a timely basis, or at all, from such third parties and on commercially suitable terms could affect its ability to provide its services. 

Outlook

ABH Healthcare is engaged in the business of establishing, maintaining, assisting healthcare services in India, in the form of Super Speciality Hospitals and allied services such as Laboratories & Diagnostic Centres, Blood Bank and other related services. It offers medical services across multiple specialties, covering a wide range of healthcare needs ensuring that it provides comprehensive, quality treatments across a wide spectrum of healthcare needs. On the concern side, if it is unable to keep pace with technological changes, new equipments and service introductions, changes in patients’ needs and evolving industry standards as well as failure or malfunction of its medical or other equipments, its business and financial condition may be adversely affected.

The company is coming out with a maiden IPO of 34,29,600 equity shares of face value of Rs 10 each. The issue has been offered in a price band of Rs 96-102 per equity share. The aggregate size of the offer is around Rs 32.92 crore to Rs 34.98 crore based on lower and upper price band respectively. On performance front, revenue from operations increased by 6.58% from Rs 4,926.71 lakh in Fiscal 2025 to Rs 5,250.69 lakh in Fiscal 2026. Profit for the year increased by 5.47% from Rs 534.70 lakh in Fiscal 2025 to Rs 563.94 lakh in Fiscal 2026.

Meanwhile, it will focus on attracting qualified and experienced clinicians to ensure that the healthcare services provided to its patients are of quality. By establishing quality hospital in the region where it operates, it has successfully created an environment that attracts professionals who are renowned in their fields with experience in medical institutes globally. Going forward, to improve accessibility to critical, time-sensitive medical treatment, it plans to establish multiple urgent care centers in key locations across its surrounding towns. Without significant capital investment, these centers will provide immediate intervention for life-threatening conditions such as acute stroke, respiratory distress, and cardiac arrest. By offering rapid diagnosis and stabilization, they will serve as essential points of care, bridging the gap between primary care and emergency services.